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Letters to the EditorReply to: ‘‘Time is a crucial factor for the use of oncological treatment
for post-transplantation recurrence of hepatocellular carcinoma’’In our recent paper, we observed that the more indolent
course of late HCC recurrences, occurring more than 2 years after
LT, is associated with a reduction in the risk of death of more than
70% if compared to early recurrent patients. Noteworthy, the
median TTR of those 5 patients of our series remaining alive
and cured after surgical resection of their recurring HCC
approached 5 years (58.7 months). In these patients HCC recur-
rence is probably the result of the reactivation of a few dormant
HCC cells, engrafted at the time of LT: in such circumstances a
prompt surgical removal may be associated with some chance
of cure. Conversely, when facing early recurrences after LT, an
aggressive surgical treatment may be useless and even harmful
considering the high risk of further growth of occult disease. As
suggested [3], the ﬁrst step in the treatment of an early intrahe-
patic recurrence may be a loco-regional treatment, used as a test
of time in order to observe potential progression in other sites. In
the instance of an early recurrence emerging in multiple organs,
or when facing an untreatable progression, we recommend the
use of sorafenib at the onset of recurrence, considering its safety
and possible beneﬁt in survival [1,6].
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We thank Dr. Felga and colleagues for their comments on our
article demonstrating the efﬁcacy of sorafenib treatment in case
of recurrent hepatocellular carcinoma (HCC) after liver transplan-
tation (LT) [1]. In their experience with 20 of such patients in
Brazil they observed that time-to-recurrence (TTR) after LT might
be inﬂuenced by adverse baseline tumor biology – i.e., G3 tumors
and presence of macrovascular invasion – and tumor load,
suggesting that early recurrences within 1 year after LT were
characterized by a worse prognosis, while patients with later
recurrences were more prone to receive some form of HCC
treatment and had a higher median survival.
Indeed, we thank for the opportunity to add to our previous
report a few comments on the supposed differences among early
vs. late recurrences after LT. Differently from Dr. Felga et al., we
did not ﬁnd that HCC factors such as tumor load (within/beyond
Milan criteria at radiology and pathology), presence of microvas-
cular invasion (mVI) and presence of microsatellites were
correlated with TTR (with p = 0.217, 0.510, 0.128, and 0.510
respectively at the Pearson Chi-square test). Only a higher num-
ber of nodules per se – evaluated as a continuous variable at
pre-LT radiology and at histology – appeared to be associated
with an earlier recurrence (p = 0.019 and 0.036 respectively at
the Kruskal-Wallis test). Therefore, even if the aforementioned
HCC characteristics are associated with the probability of tumor
recurrence after LT [2], they are apparently poor predictors of
the TTR after LT.
Although TTR is not predictable, timing and pattern of the
observed recurrences may happen to be correlated. In our series,
patients with early recurrence suffered that in multiple organs
more frequently than patients with a later recurrence (63.6% vs.
28.6%, p = 0.43). This resulted in a reduced eligibility to curative
treatments – such as surgical resection or radiofrequency abla-
tion – that were applied only in 18.2% of those with early recur-
rence vs. 75% of late recurring patients (p = 0.001), since also the
median time to untreatable progression/presentation was signif-
icantly different among groups [0.5 months (0.5–54.8) vs.
11.1 months (0.5–77.4), p = 0.131 respectively]. As brilliantly sta-
ted by Toso et al. [3], early recurrences may be linked to remain-
ing extrahepatic HCCs deposits left at the time of LT, or result
from the post-transplant engraftment of aggressive circulating
HCC clones. Such a tumor aggressiveness, that inﬂuences treat-
ment applicability and patients outcome, has been previously
demonstrated by different authors [4,5] and conﬁrmed herein
by Felga et al. prognosis. Liver Transpl 2004;10:534–540.
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JOURNAL OF HEPATOLOGYontroversy on the role of FoxP3+ regulatory T cells in ﬁbrogenesis in
chronic hepatitis C virus infections
o the Editor:
e read with interest the manuscript by Langhans and
olleagues. The authors identiﬁed a subset of intrahepatic FoxP3+
egulatory T cells (Treg) that produce IL-8 in chronic hepatitis C
irus (HCV) infected patients, and the authors suggested that
hese cells promote liver ﬁbrosis through stimulation of hepatic
tellate cells [1]. This article is very timely and highly relevant
n an age where novel therapeutic strategies based on the use
f direct-acting antivirals are expected to lead to viral eradication
n most chronic HCV patients who undergo treatment. However,
espite dramatically improved viral eradication rates, the detri-
ental consequences of liver pathology and ﬁbrosis, such as
ecompensated liver cirrhosis and hepatocellular carcinoma,
emain an issue, and detailed understanding of ﬁbrosis is needed.
The paper by Langhans et al. makes an important contribution
o better understand the role of Treg in ﬁbrosis in chronic HCV by
howing that IL-8-secreting Treg are enriched in the liver and are
etected especially at the transition areas of ﬁbrosis. Although
his is a very intriguing observation that identiﬁes a functionally
pecialized fraction within the Treg pool of cells, it also raises a
umber of questions. First of all, only a minority of liver FoxP3+
reg produce IL-8 (on average 4.5%), while it is known that
upffer cells, but also hepatocytes, endothelial cells, epithelial
ells and ﬁbroblasts are major sources of IL-8. The paper does
ot clarify what determines that Treg-derived IL-8 promotes
brinogenesis, whereas the importance of IL-8 derived from
ther liver cells is still unknown. Importantly, the IL-8 levels
ecreted by these cells are likely magnitudes higher. Next, an
nteresting ﬁnding from the microarray analysis presented by
he authors is that Treg clones generated from cells from chronic
CV patients also express IFN-c, besides IL-8. Both cytokines are
xpressed at lower levels by clones from patients with spontane-
usly resolved HCV infections. It would be relevant to examine
hether the IL-8/IFN-c producing Treg clones also possess effec-
or activities that are independent of IL-8 and may promote ﬁbro-
is. In this respect it is important to mention that a general
eature of tissue-residing T cells is an activated phenotype [2],
hich may be more pronounced in livers from persistent vs.
esolved patients. Finally, IFN-c producing capacity is generally
ot a feature of FoxP3+ Treg, which raises the question whether
he Treg clones described by Langhans et al., are representative
or intrahepatic FoxP3+ Treg in vivo.
In apparent contradiction with the population of IL-8 secret-
ng Treg described by Langhans et al., we recently published data
in the Journal of Hepatology in line with the widely accepted par-
adigm that FoxP3+ Treg limit immunopathology at the cost of
insufﬁcient protective pathogen-speciﬁc immune responses
[3,4]. Our ﬁndings showed that FoxP3+ Treg were abundantly
present in chronic HCV infected livers, but not in healthy livers,
and primarily resided within the portal tracts in close proximity
to the lymphocytic inﬁltrate, which is in line with previous
ﬁndings published in the Journal of Hepatology by two indepen-
dent groups [5,6]. Additionally, in our hands, higher frequencies
of FoxP3+ Treg were present in livers of chronic HCV patients
without or with mild ﬁbrosis [4]. Although Langhans and
colleagues kindly referred to our publication, they omitted to
discuss these key ﬁndings.
If it holds true that IL-8 production by FoxP3+ Treg substan-
tially contributes to liver ﬁbrosis, we propose that, analogous to
TGF-b [7–9], FoxP3+ Treg play a dual role both promoting and
limiting ﬁbrosis. While FoxP3+ Treg generally seem to protect
against liver ﬁbrosis [4], the small subset of IL-8-expressing
FoxP3+ Treg may deteriorate liver pathology [1]. Importantly, in
contrast to what is often postulated, we recently showed that
FoxP3+ Treg are retained in the liver long after HCV eradication,
even after HCV RNA was undetectable in serum for more than
12 months, suggesting ongoing immunopathology and regulation
by intrahepatic FoxP3+ Treg [10]. These FoxP3+ Treg differed
phenotypically from their counterparts present during ongoing
persistent infection. We strongly feel that these Treg are unlikely
to further promote ﬁbrosis in the absence of HCV, but rather act
as memory Treg. The question remains whether IL-8 production
by FoxP3+ Treg is maintained after viral eradication, or whether
IL-8 expression is reduced. Our data as well as Langhans’ ﬁndings
demonstrate convincingly that the Treg compartment in HCV
infected livers is heterogeneous, and more detailed analysis, both
phenotypically as well as functionally is urgently needed to elu-
cidate the importance of FoxP3+ Treg in disease progression in
the inﬂamed liver.
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